{"id":"arm-d-folfiri-or-folfox-plus-cetuximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Acneiform rash"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL1201577","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T13:07:27.846371","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFIRI (fluorouracil, leucovorin, irinotecan) and FOLFOX (fluorouracil, leucovorin, oxaliplatin) are standard chemotherapy backbones that inhibit DNA synthesis and cause cell death. Cetuximab is a chimeric monoclonal antibody targeting EGFR, which blocks ligand-induced receptor activation and downstream proliferation signaling. The combination leverages both cytotoxic chemotherapy and targeted EGFR inhibition to enhance anti-tumor activity.","oneSentence":"This combination regimen uses chemotherapy (FOLFIRI or FOLFOX) to kill rapidly dividing cancer cells, combined with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to prevent tumor growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:23.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer, KRAS wild-type"},{"name":"Advanced colorectal cancer"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT01878422","phase":"PHASE3","title":"Sequential Treatment Strategy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2007-11","conditions":"Metastatic Colorectal Cancer","enrollment":376},{"nctId":"NCT01276379","phase":"PHASE2","title":"Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab","status":"COMPLETED","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2011-01","conditions":"Colorectal Cancer","enrollment":221},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT00077233","phase":"PHASE3","title":"FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-12","conditions":"Colorectal Cancer","enrollment":238}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FOLFIRI or FOLFOX plus CETUXIMAB"],"phase":"phase_3","status":"active","brandName":"Arm D: FOLFIRI or FOLFOX plus CETUXIMAB","genericName":"Arm D: FOLFIRI or FOLFOX plus CETUXIMAB","companyName":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","companyId":"istituto-romagnolo-per-lo-studio-dei-tumori-dino-amadori-irst-s-r-l-irccs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses chemotherapy (FOLFIRI or FOLFOX) to kill rapidly dividing cancer cells, combined with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to prevent tumor growth. Used for Metastatic colorectal cancer, KRAS wild-type, Advanced colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}